A company that specialises in the use of cannabis as a form of medication have come up with a revolutionary pain patch that can be used to treat diabetic nerve pain and symptoms of fibromyalgia. This could change the way cannabis is viewed in the medical world forever.

The new medications are designed to be administered as transdermal patches, which are basically adhesive patches that are stuck to the skin and release certain chemicals over time to help combat neurological nerve pain associated with diabetes and fibromyalgia. Using this medium means a controlled dose of the medication can be administered on a daily basis, with no negative side effects discovered so far.

Cannabis Science, the company who originally designed the patches, said:

“Promote healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive which will be containing high potency cannabinoid (CBD) extract that slowly enters into the bloodstream and then penetrates the central nervous system of the patient delivering the pain relief sought.”

CBD is the second most major cannabinoid contained in cannabis, the main one being THC. CBD has incredible pain relieving and anti-inflammatory properties and comes from a completely natural source with very few side effects, including the hallucinogenic effects commonly associated with THC.

Mr Raymond C Dabney, CEO of Cannabis Science stated that:

“The development of these two new pharmaceutical medicinal applications are just the tip of the iceberg for what we see as the future for Cannabis Science. While we strive to increase our land capacity for growth and facilities to produce our own product to supply our scientists with proprietary materials to make these formulations, we are also busy researching more potential needs for Cannabis related medical applications and developing the methods for delivery of these medications.”

Fibromyalgia is thought to affect up to 10% of us, with a huge number of sufferers not yet diagnosed. Nerve neuropathy diabetic pain affects a large number of people worldwide, and this new treatment will be a massive step in the right direction towards limiting certain symptoms, and maybe even curing these illnesses for good.

Mr Dabney concludes:

“As more states nationwide legislate for the legalization of cannabis and cannabis-derived medications, we here at Cannabis Science are focused on developing pharmaceutical formulations and applications to supply the huge growing demand expected over the coming few years.”